1208112-49-5Relevant academic research and scientific papers
Mycobactin Analogues with Excellent Pharmacokinetic Profile Demonstrate Potent Antitubercular Specific Activity and Exceptional Efflux Pump Inhibition
Shyam, Mousumi,Verma, Harshita,Bhattacharje, Gourab,Mukherjee, Piyali,Singh, Samsher,Kamilya, Sujit,Jalani, Pushpendu,Das, Swetarka,Dasgupta, Arunava,Mondal, Abhishake,Das, Amit Kumar,Singh, Amit,Brucoli, Federico,Bagnéris, Claire,Dickman, Rachael,Basavanakatti, Vinay N.,Naresh Babu, Patibandla,Sankaran, Vadivelan,Dev, Abhimanyu,Sinha, Barij Nayan,Bhakta, Sanjib,Jayaprakash, Venkatesan
, p. 234 - 256 (2022/01/20)
In this study, we have designed and synthesized pyrazoline analogues that partially mimic the structure of mycobactin, to address the requirement of novel therapeutics to tackle the emerging global challenge of antimicrobial resistance (AMR). Our investigation resulted in the identification of novel lead compounds 44 and 49 as potential mycobactin biosynthesis inhibitors against mycobacteria. Moreover, candidates efficiently eradicated intracellularly surviving mycobacteria. Thermofluorimetric analysis and molecular dynamics simulations suggested that compounds 44 and 49 bind to salicyl-AMP ligase (MbtA), a key enzyme in the mycobactin biosynthetic pathway. To the best of our knowledge, these are the first rationally designed mycobactin inhibitors to demonstrate an excellent in vivo pharmacokinetic profile. In addition, these compounds also exhibited more potent whole-cell efflux pump inhibition than known efflux pump inhibitors verapamil and chlorpromazine. Results from this study pave the way for the development of 3-(2-hydroxyphenyl)-5-(aryl)-pyrazolines as a new weapon against superbug-associated AMR challenges.
Chemical scaffolds with structural similarities to siderophores of nonribosomal peptide-polyketide origin as novel antimicrobials against Mycobacterium tuberculosis and Yersinia pestis
Ferreras, Julian A.,Gupta, Akash,Amin, Neal D.,Basu, Arijit,Sinha, Barij N.,Worgall, Stefan,Jayaprakash, Venkatesan,Quadri, Luis E.N.
supporting information; scheme or table, p. 6533 - 6537 (2011/12/04)
Mycobacterium tuberculosis (Mtb) and Yersinia pestis (Yp) produce siderophores with scaffolds of nonribosomal peptide-polyketide origin. Compounds with structural similarities to these siderophores were synthesized and evaluated as antimicrobials against Mtb and Yp under iron-limiting conditions mimicking the iron scarcity these pathogens encounter in the host and under standard iron-rich conditions. Several new antimicrobials were identified, including some with increased potency in the iron-limiting condition. Our study illustrates the possibility of screening compound libraries in both iron-rich and iron-limiting conditions to identify antimicrobials that may selectively target iron scarcity-adapted bacteria and highlights the usefulness of building combinatorial libraries of compounds having scaffolds with structural similarities to siderophores to feed into antimicrobial screening programs.
Towards development of selective and reversible pyrazoline based MAO-inhibitors: Synthesis, biological evaluation and docking studies
Sahoo, Anasuya,Yabanoglu, Samiye,Sinha, Barij N.,Ucar, Gulberk,Basu, Arijit,Jayaprakash, Venkatesan
supporting information; experimental part, p. 132 - 136 (2010/04/05)
Ten novel 3,5-diaryl pyrazolines were synthesized and investigated for their monoamine oxidase (MAO) inhibitory property. All the molecules were found to be reversible and selective inhibitor for either one of the isoform (MAO-A or MAO-B). Further insights in the theoretical evaluation of the possible interactions between the compounds and monoamine oxidases (MAO-A or MAO-B) have been developed through docking studies. The theoretical values are in congruence with their experimental values.
